Hettle R - Search Results

1

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.

Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Siddiqui MK, et al. Among authors: hettle r. Curr Med Res Opin. 2018 Aug;34(8):1361-1371. doi: 10.1080/03007995.2017.1407303. Epub 2017 Nov 28. Curr Med Res Opin. 2018. PMID: 29149804

2

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.

Hettle R, Harty G, Wong SL. Hettle R, et al. J Med Econ. 2018 Jul;21(7):676-686. doi: 10.1080/13696998.2018.1461630. Epub 2018 Apr 16. J Med Econ. 2018. PMID: 29618273 Free article.

3

Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.

Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Gorrod HB, et al. Among authors: hettle r. Value Health. 2019 Jul;22(7):772-776. doi: 10.1016/j.jval.2018.11.015. Epub 2019 May 17. Value Health. 2019. PMID: 31277823 Free article. Clinical Trial.

4

Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.

Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Bell Gorrod H, et al. Among authors: hettle r. Adv Ther. 2020 Jan;37(1):225-239. doi: 10.1007/s12325-019-01140-z. Epub 2019 Nov 7. Adv Ther. 2020. PMID: 31701485 Clinical Trial.

5

Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA. Mistry R, et al. Among authors: hettle r. Curr Med Res Opin. 2018 Dec;34(12):2143-2150. doi: 10.1080/03007995.2018.1503484. Epub 2018 Aug 17. Curr Med Res Opin. 2018. PMID: 30032697

6

Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.

Large S, Hettle R, Balakumaran A, Wu E, Borse RH. Large S, et al. Among authors: hettle r. J Med Econ. 2018 Nov 13:1-10. doi: 10.1080/13696998.2018.1534738. Online ahead of print. J Med Econ. 2018. PMID: 30303022 Free article.

7

Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.

Hettle R, Posnett J, Borrill J. Hettle R, et al. J Med Econ. 2015;18(7):516-24. doi: 10.3111/13696998.2015.1024682. Epub 2015 Apr 7. J Med Econ. 2015. PMID: 25735651 Free article. Clinical Trial.

8

Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms.

Hettle R, Borrill J, Suri G, Wulff J. Hettle R, et al. Clinicoecon Outcomes Res. 2015 Nov 26;7:615-27. doi: 10.2147/CEOR.S92078. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 26648747 Free PMC article.

9

Generating Health State Utility Values from Fact-Ovarian Data Collected in a Phase Ii Maintenance Study in Platinum Sensitive Recurrent Ovarian Cancer (Study 19): A Comparison of Mapping Algorithms.

Hettle R, Borrill J, Suri G, Wulff J. Hettle R, et al. Value Health. 2014 Nov;17(7):A646. doi: 10.1016/j.jval.2014.08.2341. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202324 Free article. No abstract available.

10

Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Wirth D, Dass R, Hettle R. Wirth D, et al. Among authors: hettle r. BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2. BMC Health Serv Res. 2017. PMID: 28270207 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters